REGENXBIO Inc. (RGNX)
| Market Cap | 1.01B |
| Revenue (ttm) | 480.03M |
| Net Income (ttm) | 73.64M |
| Shares Out | 43.25M |
| EPS (ttm) | 1.74 |
| PE Ratio | 13.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,573 |
| Open | 22.57 |
| Previous Close | 22.69 |
| Day's Range | 22.44 - 23.08 |
| 52-Week Range | 18.69 - 36.35 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 49.06 (+116.1%) |
| Earnings Date | Nov 3, 2022 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is 49.06, which is an increase of 116.12% from the latest price.
News
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conf...
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 RGX-314 program for the treatment ...
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatm...
RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events Patients treated with RGX-314 in Cohorts 1-3 demonstrated clinically meaningful improve...
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational H...
ROCKVILLE, Md. , Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal delivery ...
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Company announced positive interim data from and the expansion of Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery RGX-314 continues to be well tolerated i...
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
ROCKVILLE, Md. , Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, Oct...
REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting
Company to host conference call on Monday, October 3 rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE® trial ROCKVILLE, Md.
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treat...
- New data in Cohort 3 using pivotal program dose level demonstrates largest median reduction in CSF GAGs, continuing to approach normal levels at 48 weeks - RGX-121, a one-time gene therapy...
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
ROCKVILLE, Md. , Aug. 23, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place from...
REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ROCKVILLE, Md. , Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C.
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -9.72% and 25.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOS...
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-...
FDA will consider an accelerated approval pathway for RGX-121; BLA filing expected in 2024 Pivotal program is active and enrolling patients RGX-121 is a potential first-in-class, one-time gene therapy f...
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational...
ROCKVILLE, Md. , Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m.
REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial
85 subjects dosed across five cohorts in AAVIATE ® trial evaluating RGX-314 for the treatment of wet AMD using suprachoroidal delivery Company expects to report additional suprachoroidal data later thi...
REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility
In-house facility to produce NAV Technology-based AAV gene therapies at 2,000 liters scale $65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery C...
Jennifer Zachary Joins REGENXBIO Board of Directors
ROCKVILLE, Md. , June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022.
5 Small-Cap S&P Stocks To Buy With The Most Upside
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-ca...
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , May 4, 2022 /PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024 Enrollment ongoing ...
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
ROCKVILLE, Md. , May 3, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtuall...
3 Small-Cap Medical Stocks With Big Momentum
Now is a good time to take a closer look at these stocks.